Point Therapeutics to Present Novel Dual Mechanism of Action for Talabostat During Research and Development Day on April 25; Ne

Point Therapeutics, Inc. (NASDAQ:POTP) announced it will
comprehensively review the novel dual mechanism of action for its lead
compound, talabostat, a targeted anti-cancer therapy. For the first
time, Point will unveil the identified targets and cellular
biochemistry responsible for talabostat's anti-tumor activity. The
dual mechanism of action is based talabostat's inhibition of
fibroblast activation protein (FAP) inhibition and talabostat's
immunostimulatory properties. The R&D Day will be at the Four Seasons
New York on April 25, 2006 from 4:30 to 6:30 pm ET.
   The event will feature a scientific overview of talabostat by Dr.
Barry Jones, Chief Scientific Officer at Point Therapeutics, and Dr.
Charles Dinarello, Professor of Medicine, University of Colorado
School of Medicine, who will review the peer-reviewed data available
about the compound and its mechanism of action.
   "We are pleased to have an opportunity to comprehensively present
talabostat's mechanism of action during our upcoming R&D Day. Our
extensive preclinical studies support an exciting, novel dual
mechanism of action for talabostat. These studies are the foundation
of talabostat's clinical program, which includes two Phase 3 studies
in non-small cell lung cancer and ongoing Phase 2 studies in
metastatic melanoma, chronic lymphocytic leukemia and pancreatic
cancer," said Don Kiepert, President and CEO of Point Therapeutics.
   For reservations, please contact Sarah Cavanaugh at 617-933-7508
or [e-mail].

   About Point Therapeutics, Inc.:

   Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.
In addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as a
vaccine adjuvant.

   Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements with respect to the company's clinical development programs
and the timing of initiation and completion of its clinical trials.
Forward-looking statements are statements that are not historical
facts, and can be identified by, among other things, the use of
forward-looking language, such as "believes," "feels," "expects,"
"may," "will," "should," "seeks," "plans," "schedule to,"
"anticipates" or "intends" or the negative of those terms, or other
variations of those terms of comparable language, or by discussions of
strategy or intentions. A number of important factors could cause
actual results to differ materially from those projected or suggested
in the forward looking statement, including the risk factors described
in Point's quarterly report on Form 10-K for the year ended December
31, 2005 and from time to time in Point's periodic and other reports
filed with the Securities and Exchange Commission.